Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Fluconazole and Itraconazole on Erdafitinib PK
NCT03135106Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of erdafitinib in urothelial carcinoma (UC) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Analyte Concentration at 672 hours, Area Under the Plasma Analyte Concentration-time Curve From Time 0 to One Week Post-dose and 2 more. Started Apr 2017; status: completed.
02
Drugs
erdafitinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03135106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03135106.